Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZ235 in Advanced Endometrial Carcinoma
NCT01290406Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Mar 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of dactolisib in endometrial carcinoma, sponsored by Novartis. Primary endpoint: Overall Response Rate. Planned start Mar 2012; status: withdrawn.
02
Drugs
dactolisib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT01290406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01290406.